Quotient (QTNT)

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient's proprietary multiplex microarray technology, offers the world's first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

Company profile

Ticker

QTNT

Exchange

NASDAQ

Website

www.quotientbd.com

CEO

Franz Walt

Incorporated

Jersey

Location

Jersey

Fiscal year end

Mar 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

In Vitro & In Vivo Diagnostic Substances

Ortho Clinical Diagnostics • QuidelOrtho • Idexx Laboratories • Myriad Genetics • Neogen • Lantheus • QuidelOrtho • Meridian Bioscience • Celldex Therapeutics • Achieve Life Sciences ...

SEC CIK

0001596946

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Alba Bioscience Limited • QBD (QS IP) Limited • Quotient Biodiagnostics, Inc. • Quotient Biocampus Limited • Quotient Iberia, S.L. • Quotient Suisse SA ...

QTNT stock data

1M 1Y 5Y

News

From Benzinga Pro

Stocks That Hit 52-Week Lows On Tuesday

9 Aug 22

On Tuesday, 73 companies hit new 52-week lows.

Quotient Q1 EPS $(0.37) Down From $(0.24) YoY, Sales $8.81M Miss $9.55M Estimate

9 Aug 22

Quotient (NASDAQ:QTNT) reported quarterly losses of $(0.37) per share. This is a 54.17 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $8.81

Earnings Scheduled For August 9, 2022

9 Aug 22

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

Quotient Limited And InfYnity Biomarkers Announce Partnership To Expand MosaiQ Infectious Disease Menu

12 Jul 22

$1.4 Million Bet On This Healthcare Stock? 4 Penny Stocks Insiders are Buying

7 Jul 22

Press releases

From Benzinga Pro

Quotient Limited Provides First Quarter Fiscal 2023 Results and Business Update

9 Aug 22

MosaiQ™ Solution Commercial Execution: Extended IH Launch: $1.4 million MosaiQ bookings completed with $0.4 million in revenue in the first quarterDistribution Network: Ten agreements signed with more in process;

Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call on August 9th

2 Aug 22

JERSEY, Channel Islands, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022

Quotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease Menu

12 Jul 22

JERSEY, Channel Islands, July 12, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with InfYnity Biomarkers, an R&D firm dedicated to

Quotient Limited Announces Equity Awards

1 Jul 22

Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares and Pre-Funded Warrants

29 Jun 22

Analyst ratings and price targets

Last 3 months

Average target

$2.25

Low target

$1.50

High target

$3.00

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

8 Aug 22

15 Aug 22

31 Mar 23

Financial summary

Financial statements Chart QTNT financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 22	Mar 21	Mar 20	Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	54.88M	54.88M	54.88M	54.88M	54.88M	54.88M
Cash burn (monthly)	6.31M	5.66M	12.91M	11.43M	11.84M	10.21M
Cash used (since last report)	9.63M	8.65M	19.71M	17.45M	18.08M	15.59M
Cash remaining	45.24M	46.23M	35.16M	37.42M	36.8M	39.29M
Runway (months of cash)	7.2	8.2	2.7	3.3	3.1	3.8

Beta Read what these cash burn values mean

Financial data from Quotient earnings reports.

Recent insider trades

QTNT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
31 Jul 22	Catherine Larue	Ordinary Shares	Option exercise	Acquire M	No	No	6,917	40,294
31 Jul 22	Catherine Larue	RSU Ordinary Shares	Option exercise	Dispose M	No	No	6,917	6,917
31 Jul 22	Shroff Zubeen	Ordinary Shares	Option exercise	Acquire M	No	No	13,538	131,999
31 Jul 22	Shroff Zubeen	RSU Ordinary Shares	Option exercise	Dispose M	No	No	2,668	2,668
31 Jul 22	Shroff Zubeen	RSU Ordinary Shares	Option exercise	Dispose M	No	No	10,870	10,868
31 Jul 22	Hallsworth Frederick	Ordinary Shares	Option exercise	Acquire M	No	No	6,917	223,005
31 Jul 22	Hallsworth Frederick	RSU Ordinary Shares	Option exercise	Dispose M	No	No	6,917	6,917
31 Jul 22	Wilkerson L John	Ordinary Shares	Option exercise	Acquire M	No	No	11,660	106,618
31 Jul 22	Wilkerson L John	RSU Ordinary Shares	Option exercise	Dispose M	No	No	790	792
31 Jul 22	Wilkerson L John	RSU Ordinary Shares	Option exercise	Dispose M	No	No	10,870	10,868

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

QTNT institutional ownership history Ownership history

56.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	78	84	-7.1%
Opened positions	6	10	-40.0%
Closed positions	12	25	-52.0%
Increased positions	17	33	-48.5%
Reduced positions	35	30	+16.7%

13F shares	Current	Prev Q	Change
Total value	91.24M	252.34M	-63.8%
Total shares	76.04M	79.53M	-4.4%
Total puts	11.4K	465.4K	-97.6%
Total calls	150.8K	480.1K	-68.6%
Total put/call ratio	0.1	1.0	-92.2%

Largest owners	Shares	Value	Change
Perceptive Advisors	16.2M	$19.44M	0.0%
Pura Vida Investments	10.16M	$12.19M	+17.4%
Polar Capital	9.25M	$11.1M	0.0%
Highbridge Capital Management	9.12M	$10.94M	+24.2%
BLK Blackrock	5.38M	$6.46M	-0.9%
MS Morgan Stanley	4.83M	$5.8M	+29.8%
Clearbridge Advisors	4.26M	$5.11M	+0.8%
AMP Ameriprise Financial	3.67M	$4.41M	-28.7%
TimesSquare Capital Management	2.72M	$3.26M	-1.6%
Vanguard	1.77M	$2.12M	-2.4%

Largest transactions	Shares	Bought/sold	Change
CS Credit Suisse	0	-2.39M	EXIT
Highbridge Capital Management	9.12M	+1.78M	+24.2%
Artisan Partners Limited Partnership	438.44K	-1.71M	-79.6%
Pura Vida Investments	10.16M	+1.51M	+17.4%
AMP Ameriprise Financial	3.67M	-1.48M	-28.7%
MS Morgan Stanley	4.83M	+1.11M	+29.8%
Susquehanna International	0	-311.33K	EXIT
BCS Barclays	16.74K	-300.73K	-94.7%
Millennium Management	0	-279.54K	EXIT
Alliancebernstein	42.1K	-233.57K	-84.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Insignia Systems • Grifols SA - ADR - Level III

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Allan, allergy, ARC, autoimmune, awarded, CDS, classification, covenant, deducted, deducting, deemed, eligible, firm, incurrence, inflation, inflationary, leaseback, lieu, listing, Lux, maximum, MDS, payout, permanent, quality, ratio, recently, recovery, reinforce, repay, Robb, support, upcoming

Removed: adapted, affected, application, applying, appointment, approved, assessment, ASU, August, Authorization, bond, calculating, carried, challenge, clear, combat, combined, commence, Committee, complexity, concordance, conduct, consisted, contract, declared, dedicated, delayed, designated, developed, difficult, distancing, distribution, eased, Emergency, enhance, enhanced, equally, EUA, evolving, expanded, expanding, extent, external, FASB, flow, forfeited, growing, growth, guidance, Health, hedged, Hedging, highly, hiring, impacted, implemented, inducement, initially, institutional, internal, invest, joining, linked, liquidated, lockdown, Manuel, mark, marked, menu, minimal, mitigate, mitigation, moderated, modified, negatively, November, optimized, order, outbreak, phase, postponed, qualitative, quarantine, quoted, rank, realization, receive, recommence, recommended, redeem, relate, relevant, removed, Remuneration, repeatedly, response, restarted, restarting, restriction, retrospective, robust, Rule, salary, scope, segregate, sensitivity, September, shift, social, specificity, spend, spite, spot, standing, stopping, strain, study, submission, submitted, Subtopic, terminated, termination, test, uncertain, unsecured, unsubordinated, USA, validation, vary, varying, verification, vest, widespread, written, yield

From filing 10-Q 2023 Q1

Financial reports

View all